Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | Unmet needs in BPDCN

Marco Herling • 12 Jun 2022
EHA 2022
Blastic Plasmacytoid Dendritic Cell Neoplasm Rare Diseases Tagraxofusp

In this video, Marco Herling, MD, University of Leipzig, Leipzig, Germany, briefly discusses unmet needs in blastic plasmacytoid dendritic cell neoplasm (BPDCN), highlighting the need to continue improving methods used in the diagnosis of disease, and the importance of keeping patients in durable remissions. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Marco Herling

1:00
Unmet needs in BPDCN: CNS involvement & the importance of intrathecal chemotherapy prophylaxis
Marco Herling • 25 Apr 2023
1:41
Improvements in the awareness and diagnosis of BPDCN
Marco Herling • 25 Apr 2023
1:15
Managing patients with transplant-ineligible BDPCN with tagraxofusp
Marco Herling • 25 Apr 2023
1:23
The challenge of relapse in transplant-eligible & transplant-ineligible patients with BDPCN
Marco Herling • 25 Apr 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals